Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation

Nicole P. Daukshus; Anthony Cirincione; Molly Siver; Sherry Mathew; Binni Kunvarjee; Amelia Chan; Jaap Jan Boelens; Susan K. Seo; Genovefa A. Papanicolaou; Nancy A. Kernan

doi:10.1093/jpids/piac017

Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation

Nicole P. Daukshus
, Anthony Cirincione
, Molly Siver
, Sherry Mathew
, Binni Kunvarjee
, Amelia Chan
, Jaap Jan Boelens
, Susan K. Seo
, Genovefa A. Papanicolaou
, Nancy A. Kernan

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

There are limited data for letermovir as primary cytomegalovirus (CMV) prophylaxis in patients less than 18 years of age. We report 9 adolescent patients who received letermovir following hematopoietic cell transplantation. No patients developed clinically significant CMV while taking letermovir. Letermovir was well tolerated and efficacious in preventing CMV infections.

Original language	English (US)
Pages (from-to)	337-340
Number of pages	4
Journal	Journal of the Pediatric Infectious Diseases Society
Volume	11
Issue number	7
DOIs	https://doi.org/10.1093/jpids/piac017
State	Published - Jul 1 2022
Externally published	Yes

All Science Journal Classification (ASJC) codes

Pediatrics, Perinatology, and Child Health
Infectious Diseases

Keywords

adolescents
cytomegalovirus
hematopoietic cell transplant
letermovir

Access to Document

10.1093/jpids/piac017

Cite this

Daukshus, N. P., Cirincione, A., Siver, M., Mathew, S., Kunvarjee, B., Chan, A., Boelens, J. J., Seo, S. K., Papanicolaou, G. A., & Kernan, N. A. (2022). Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation. Journal of the Pediatric Infectious Diseases Society, 11(7), 337-340. https://doi.org/10.1093/jpids/piac017

@article{3de607d6628647b09e980763ecea32f6,

title = "Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation",

abstract = "There are limited data for letermovir as primary cytomegalovirus (CMV) prophylaxis in patients less than 18 years of age. We report 9 adolescent patients who received letermovir following hematopoietic cell transplantation. No patients developed clinically significant CMV while taking letermovir. Letermovir was well tolerated and efficacious in preventing CMV infections.",

keywords = "adolescents, cytomegalovirus, hematopoietic cell transplant, letermovir",

author = "Daukshus, \{Nicole P.\} and Anthony Cirincione and Molly Siver and Sherry Mathew and Binni Kunvarjee and Amelia Chan and Boelens, \{Jaap Jan\} and Seo, \{Susan K.\} and Papanicolaou, \{Genovefa A.\} and Kernan, \{Nancy A.\}",

year = "2022",

month = jul,

day = "1",

doi = "10.1093/jpids/piac017",

language = "English (US)",

volume = "11",

pages = "337--340",

journal = "Journal of the Pediatric Infectious Diseases Society",

issn = "2048-7193",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation

AU - Daukshus, Nicole P.

AU - Cirincione, Anthony

AU - Siver, Molly

AU - Mathew, Sherry

AU - Kunvarjee, Binni

AU - Chan, Amelia

AU - Boelens, Jaap Jan

AU - Seo, Susan K.

AU - Papanicolaou, Genovefa A.

AU - Kernan, Nancy A.

PY - 2022/7/1

Y1 - 2022/7/1

N2 - There are limited data for letermovir as primary cytomegalovirus (CMV) prophylaxis in patients less than 18 years of age. We report 9 adolescent patients who received letermovir following hematopoietic cell transplantation. No patients developed clinically significant CMV while taking letermovir. Letermovir was well tolerated and efficacious in preventing CMV infections.

AB - There are limited data for letermovir as primary cytomegalovirus (CMV) prophylaxis in patients less than 18 years of age. We report 9 adolescent patients who received letermovir following hematopoietic cell transplantation. No patients developed clinically significant CMV while taking letermovir. Letermovir was well tolerated and efficacious in preventing CMV infections.

KW - adolescents

KW - cytomegalovirus

KW - hematopoietic cell transplant

KW - letermovir

UR - https://www.scopus.com/pages/publications/85133664970

UR - https://www.scopus.com/pages/publications/85133664970#tab=citedBy

U2 - 10.1093/jpids/piac017

DO - 10.1093/jpids/piac017

M3 - Article

C2 - 35472147

AN - SCOPUS:85133664970

SN - 2048-7193

VL - 11

SP - 337

EP - 340

JO - Journal of the Pediatric Infectious Diseases Society

JF - Journal of the Pediatric Infectious Diseases Society

IS - 7

ER -

Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this